The speaker is bearish, expressing deep skepticism towards the company's management and scientific claims, implying he was short the stock.

Mentioned as a negative comparison to the ATYR trade, with the speaker stating the ATYR situation is 'in some ways... worse than cassava,' which reinforces their bearish conviction on ATYR.

Cited as a successful past example of a 'binary event' short trade, similar to the speaker's current thesis on ATYR Pharma. The commentary is historical.

Described with extremely high conviction as a 'true, once in a lifetime, generational opportunity' and a stock where the speaker has immense certainty after deep research.

Highlighted for its own data integrity controversies, with a statistician from the company also being involved with Capricor's trial data, raising a red flag.

The speaker describes the company as a 'true once in a lifetime generational opportunity' in the small biotech space.

The analyst is bearish, grouping it with other companies he is skeptical of. The recommended strategy is to 'Stay short', indicating a belief that the stock is overvalued and will eventually decline.

Referenced as a past successful short position that the speaker considered a 'fraud from the start', used to establish a track record in identifying flawed biotech companies.